Poly(ADP-ribose) polymerase inhibitors combined with external beam and radioimmunotherapy to treat aggressive lymphoma

Nuclear Medicine Communications

Volumn 32, Issue 11, 2011, Pages 1046-1051

  Schaefer, Niklaus G ^a   James, Engles ^a   Wahl, Richard L ^a,b  

^a Division of Nuclear Medicine   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ABT 888; AZD 2281; lymphoma; poly(ADP ribose) polymerase inhibitor; radioimmunotherapy

Indexed keywords

GREEN FLUORESCENT PROTEIN; HISTONE H2AX; LENTIVIRUS VECTOR; LUCIFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; OLAPARIB; TOSITUMOMAB I 131; VELIPARIB;

ARTICLE; CELL COUNT; CELL GROWTH; CELL VIABILITY; COLORIMETRY; CONCENTRATION (PARAMETERS); CONFOCAL MICROSCOPY; CONTROLLED STUDY; DOUBLE STRANDED DNA BREAK; EXTERNAL BEAM RADIOTHERAPY; GROWTH CURVE; HUMAN; HUMAN CELL; LYMPHOMA CELL; NONHODGKIN LYMPHOMA; RADIATION DOSE; RADIATION EXPOSURE; RADIOIMMUNOTHERAPY; RADIOSENSITIZATION; RAJI CELL;

ANTIBODIES, MONOCLONAL; BENZIMIDAZOLES; CELL LINE, TUMOR; CELL SURVIVAL; CHEMORADIOTHERAPY; DNA BREAKS, DOUBLE-STRANDED; ENZYME INHIBITORS; HUMANS; LYMPHOMA, NON-HODGKIN; PHTHALAZINES; PIPERAZINES; POLY(ADP-RIBOSE) POLYMERASES; RADIATION, IONIZING; RADIATION-SENSITIZING AGENTS; RADIOIMMUNOTHERAPY;

EID: 80053531544     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e32834a369b     Document Type: Article

References (31)

1. Peltomaki P. Role of DNA mismatch repair defects in the pathogenesis of human cancer. J Clin Oncol 2003; 21:1174-1179. (Pubitemid 46594150)
2. Kim MY, Zhang T, Kraus WL. Poly(ADP-ribosyl)ation by PARP-1: PARlaying NAD + into a nuclear signal. Genes Dev 2005; 19:1951-1967.
3. Schreiber V, Dantzer F, Ame J-C, De Murcia G. Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol 2006; 7:517-528. (Pubitemid 44036457)
4. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361:123-134.
5. Kaminski MS, Zasadny KR, Francis IR, Milik AW, Ross CW, Moon SD, et al. Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. N Engl J Med 1993; 329:459-465. (Pubitemid 23222331)
6. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkins lymphoma. J Clin Oncol 2002; 20:2453-2463. (Pubitemid 34525730)
7. Wiseman GA, Gordon LI, Multani PS, Witzig TE, Spies S, Bartlett NL, et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 2002; 99:4336-4342. (Pubitemid 34627198)
8. Witzig TE, Flinn IW, Gordon LI, Emmanouilides C, Czuczman MS, Saleh MN, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkins lymphoma. J Clin Oncol 2002; 22:3262-3269. (Pubitemid 34831524)
9. Morschhauser F, Radford J, Van Hoof A, Vitolo U, Soubeyran P, Tilly H, et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008; 26:5156-5164.
10. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010; 11:21-28.
11. Menegakis A, Yaromina A, Eicheler W, Dörfler A, Beuthien-Baumann B, Thames HD, et al. Prediction of clonogenic cell survival curves based on the number of residual DNA double strand breaks measured by gammaH2AX staining. Int J Radiat Biol 2009; 85:1032-1041.
12. Mitchell J, Smith GC, Curtin NJ. Poly(ADP-Ribose) polymerase-1 and DNA-dependent protein kinase have equivalent roles in double strand break repair following ionizing radiation. Int J Radiat Oncol Biol Phys 2009; 75:1520-1527.
13. Baba S, Cho SY, Ye Z, Cheng L, Engles JM, Wahl RL. How reproducible is bioluminescent imaging of tumor cell growth? Single time point versus dynamic measurement approach. Mol Imaging 2007; 6:315-322. (Pubitemid 350013537)
14. Donawho CK, Luo Y, Luo Y, Penning TD, Bauch JL, Bouska JJ, et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 2007; 13:2728-2737. (Pubitemid 46795129)
15. Menear KA, Adcock C, Boulter R, Cockcroft XL, Copsey L, Cranston A, et al. 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H- phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J Med Chem 2008; 51:6581-6591.
16. Zhongli C, Vallis KA, Reilly RM. Computational analysis of the number, area and density of c-H2AX foci in breast cancer cells exposed to 111In-DTPA-hEGF or c-rays using Image-J software. Int J Radiat Biol 2009; 85 (No. 3):262-271.
17. Kummar S, Kinders R, Gutierrez ME, Rubinstein L, Parchment RE, Phillips LR, et al. Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol 2009; 27:2705-2711.
18. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361:123-134.
19. Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Nygren AO, Zander SA, et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U S A 2008; 105:17079-17084.
20. Horton TM, Jenkins G, Pati D, Zhang L, Dolan ME, Ribes-Zamora A, et al. Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity. Mol Cancer Ther 2009; 8:2232-2242.
21. Khan K, Araki K, Wang D, Li G, Li X, Zhang J, et al. Head and neck cancer radiosensitization by the novel poly(ADP-ribose) polymerase inhibitor GPI-15427. Head Neck 2010; 32:381-391.
22. Sharkey RM, Karacay H, Goldenberg DM. Improving the treatment of non-Hodgkin lymphoma with antibody-targeted radionuclides. Cancer 2010 (S4):1134-1145.
23. Jurcic JG, Larson SM, Sgouros G, McDevitt MR, Finn RD, Divgi CR, et al. Targeted alpha particle immunotherapy for myeloid leukemia. Blood 2002; 100:1233-1239. (Pubitemid 34864277)
24. Forero A, Weiden PL, Vose JM, Knox SJ, LoBuglio AF, Hankins J, et al. Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma. Blood 2004; 104:227-236. (Pubitemid 38879862)
25. Grana C, Chinol M, Robertson C, Mazzetta C, Bartolomei M, De Cicco C, et al. Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: a pilot study. Br J Cancer 2002; 86:207-212. (Pubitemid 34185147)
26. Karacay H, Sharkey RM, Gold DV, Ragland DR, McBrideWJ, Rossi EA, et al. Pretargeted radioimmunotherapy of pancreatic cancer xenografts: TF10-90Y-IMP-288 alone and combined with gemcitabine. J Nucl Med 2009; 50:2008-2016.
27. Karacay H, Sharkey RM, Gold DV, Ragland DR, McBrideWJ, Rossi EA, et al. Pretargeted radioimmunotherapy of pancreatic cancer xenografts: TF10-90Y-IMP-288 alone and combined with gemcitabine. J Nucl Med 2009; 50:2008-2016.
28. Kelly MP, Lee ST, Lee FT, Smyth FE, Davis ID, Brechbiel MW, Scott AM. Therapeutic efficacy of 177Lu-CHX-A"-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy. Prostate 2009; 69:92-104.
29. Costantini DL, Bateman K, McLarty K, Vallis KA, Reilly RM. Trastuzumabresistant breast cancer cells remain sensitive to the auger electron-emitting radiotherapeutic agent 111In-NLS-trastuzumab and are radiosensitized by methotrexate. J Nucl Med 2008; 49:1498-1505.
30. Howell RW, Goddu SM, Bishayee A, Rao DV. Radioprotection against lethal damage caused by chronic irradiation with radionuclides in vitro. Radiat Res 1998; 150:391-399. (Pubitemid 28452528)
31. Mitchell J, Smith GC, Curtin NJ. Poly(ADP-Ribose) polymerase-1 and DNA-dependent protein kinase have equivalent roles in double strand break repair following ionizing radiation. Int J Radiat Oncol Biol Phys 2009; 75:1520-1527.